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Background: Conventional prenatal screening tests, such as maternal serum tests and ultrasound scan, have
limited resolution and accuracy.
Methods: We developed an advanced noninvasive prenatal diagnosis method based on massively parallel
sequencing. The Noninvasive Fetal Trisomy (NIFTY) test, combines an optimized Student’s t-test with a locally
weighted polynomial regression and binary hypotheses. We applied the NIFTY test to 903 pregnancies and
compared the diagnostic results with those of full karyotyping.
Results: 16 of 16 trisomy 21, 12 of 12 trisomy 18, two of two trisomy 13, three of four 45, X, one of one XYY and
two of two XXY abnormalities were correctly identified. But one false positive case of trisomy 18 and one false
negative case of 45, X were observed. The test performed with 100% sensitivity and 99.9% specificity for autosomal
aneuploidies and 85.7% sensitivity and 99.9% specificity for sex chromosomal aneuploidies. Compared with three
previously reported z-score approaches with/without GC-bias removal and with internal control, the NIFTY test was
more accurate and robust for the detection of both autosomal and sex chromosomal aneuploidies in fetuses.
Conclusion: Our study demonstrates a powerful and reliable methodology for noninvasive prenatal diagnosis.
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Sex chromosomal aneuploidiesBackground
Down syndrome (Trisomy 21), Edward syndrome
(Trisomy 18) and Patau syndrome (Trisomy 13) are the
most clinically significant autosomal aneuploidies, and the
incidence of autosomal abnormalities can be as high as
one in 160 live births [1]. Turner’s syndrome (45, X),
Klinefelter’s syndrome (47, XXY) and XYY syndrome
are common sex chromosomal aneuploidies that are* Correspondence: zhangxq@genomics.org.cn
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reproduction in any medium, provided the orassociated with reproductive loss, infertility and language
development delays, among others [2-4]. Sex chromo-
somal aneuploidies occur in one out of 500 male births
and one out of 850 female births [5-8].
Conventional prenatal diagnostic methods for detecting
aneuploidies, such as karyotyping, FISH and QF-PCR,
which rely on invasive procedures, bear potential risks
for miscarriage [9,10]. Noninvasive screening for fetal
aneuploidies using maternal serum markers and ultra-
sound scans entails less risk, but offers limited sensiti-
vity and specificity [11,12].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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(cff-DNA) in 1997 [13], and they highlighted its po-
tential clinical utility as a biomarker because it can be
detected from as early as four gestational weeks. Cell-
free fetal DNA clears rapidly from the maternal circu-
lation after delivery [14-16]. However, the fraction of
fetal DNA in the maternal plasma varies from 5% to
10%, which makes it difficult to detect genetic variation
in the fetus [17,18]. Conventional molecular techniques,
such as allele-specific polymerase chain reaction (PCR)
or quantitative real-time PCR, which aim to detect fetal
chromosomal disorders, focus only on specific popula-
tions [19-21], such as fetuses with heterozygous alleles.
The recent rapid development of massively parallel se-
quencing (MPS) technology now makes it possible to
noninvasively detect fetal aneuploidies in a clinical set-
ting [22-24]. Several recent studies demonstrated that
fetal aneuploidies could be detected and quantified via
high-throughput whole-genome sequencing of maternal
plasma cell-free DNA combined with a standard z-score
test. Prior studies by Chiu et al. and Ehrich et al. suggest
that an MPS-based approach is reliable at detecting tri-
somy 21 [25,26].
In principle, an MPS-based approach that resolves whole
genome information should be applicable for detecting
aneuploidies in all of the chromosomes. Chen et al.
showed, however, that such test was less successful for
detecting trisomy 18 and trisomy 13 compared with tri-
somy 21. The mixed results may be related to the GC-bias
caused by the sample preparation or sequencing proce-
dures [27]. Quake et al. developed a method to remove the
effect of GC-bias, and thus significantly improve the sensi-
tivity of the MPS-based approach for detecting trisomy 18
and trisomy 13 [28]. Another recent study reported the
possibility of detecting sex chromosomal aneuploidies
using an internal chromosome control approach [29].
In this study, we developed an advanced GC-correlation
methodology for an MPS-based, noninvasive fetal trisomy
(NIFTY) test. Our technique has higher sensitivity and
specificity than all previously reported z-score approa-
ches for the detection of autosomal and sex chromoso-
mal aneuploidy.
Results
Study participants and data production
We enrolled 903 pregnant women with ages ranging
from 20 to 45 years. The gestational ages varied from 10
to 34 weeks, covering the first to the third trimesters.
Based on the results of full karyotyping using amniotic
fluid, 866 of the fetuses were euploid and 37 were aneu-
ploid. The cases of aneuploidy included two cases of tri-
somy 13, 12 cases of trisomy 18, 16 cases of trisomy 21,
four cases of 45,X (three typical cases of 45,X and one
mosaic case of 45, X ([27]/46, XX [23]), two cases ofXXY and one case of XYY. We obtained 2–4 million
reads for each sample. After alignment and filtering, the
average data volume for aneuploidy detection was 1.7
million uniquely aligned reads. We constructed a compre-
hensive bioinformatics pipeline to scan for fetal chromo-
somal aneuploidies. The pipeline comprised short reads
alignment, GC content correction, fetal DNA concentra-
tion estimation, t-test of a binary hypothesis, and fetal
gender classification (Figure 1).
The relationship between GC content and sequencing bias
To investigate the relationship between GC content and
sequence bias, we selected 300 control pregnancies with
normal karyotypes and plotted the relative reads cove-
rage for each chromosome against the corresponding
GC content (Additional file 1: Figure S1). The relative
reads coverage of the different chromosomes was strongly
related to the inherent chromosomal GC content, and the
correlation between the two factors varied among the
chromosomes. We observed a significant positive corre-
lation between the reads coverage and GC content for
chromosomes with an average GC content greater than
41%, whereas we observed, a significant negative corre-
lation between the reads coverage and GC content for
chromosomes with an average GC content less than 41%.
Among the chromosomes with average GC content close
to 41% the reads coverage was not correlated with GC
content (Additional file 2: Figure S2). To further investi-
gate the effect of GC content on reads coverage, we exam-
ined the hidden relationship between chromosome
structure and inherent GC content. We classified all of
the unique 35-mers in the genome into 36 levels based on
the numbers of guanine (G) and cytosine (C) bases, ran-
ging from 0 to 35. We used the 35-mer counts to cluster
the chromosomes according to their GC levels within a
matrix (Additional file 3: Figure S3). Chromosomes 19
and 22 clustered together because of their higher inherent
GC contents, while chromosome 4 and 13 clustered to-
gether for their lower inherent GC contents. The diffe-
rences in the inherent GC content of the chromosomes
combined with the sequencer-related GC-bias explained
the significant correlation between reads coverage and
corresponding GC content. For example, chromosome 13
has a relatively low GC content, the PCR and sequencing
process enriched chromosomes with higher GC content,
leading to relatively low reads coverage for chromo-
some 13 and thus a negative correlation between the
reads coverage and GC content among the chromo-
somes (Additional file 1: Figure S1).
The relationship between cell-free fetal DNA
concentration and gestational week
Previous work demonstrated that the cff-DNA concen-
tration was the lynchpin in fetus aneuploidy detection
Figure 1 The flowchart of the whole bioinformatics pipeline. A comprehensive bioinformatics pipeline, including effective short read
alignment, quality control, data correction, cell-free fetal DNA concentration estimation, and aneuploidy detection.
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we examined the relationship between cell-free fetal
DNA concentration and the gestational week. We exami-
ned the 443 plasma samples with male fetal to appraise
the approximate probability relationship. Using Losses re-
gression, we found that the amount of cff-DNA increased
significantly with the gestational week (Additional file 4:
Figure S4). The correlation coefficient of the linear regres-
sion was only 0.1246, however, indicating that there might
be a more complex mechanism driving the cff-DNA
concentrations.
Quantitative description of data volatility and tags number
The volatility of the relative reads coverage was one of
the major factors affecting the sensitivity and specificity
of aneuploidy detection. To quantify the volatility of the
relative reads coverage, we used the standard deviation
of the difference between the observed and fitted relativereads coverage. We found that for each chromosome the
standard deviation was stable when the numbers of sam-
ples was larger than 100 (Additional file 5: Figure S5).
We also found that the depth of sequencing strongly
influenced the accuracy of aneuploidy detection. We iso-
lated 150 plasma samples with euploid fetuses to inspect
the relationship between the tags number (unique reads)
and the standard deviation of relative reads coverage.
On each chromosome, the standard deviation of relative
reads coverage among the 150 samples was significantly
correlated with the numbers of tags (Additional file 6:
Figure S6). We further estimated the effects of the gesta-
tional week and the number of tags on the power of our
statistical method to detect fetal aneuploidy in chromo-
somes 13, 18, 21 and X (Additional file 7: Figure S7). In
most cases, the detection power increased with both ges-
tational week and the number of sequencing reads. We
also found that the detection power was higher when
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estimation of cff-DNA concentration.
Robust data quality control of the GC-correlation t-test
Several indicators were used to judge the quality of the
sequence data. We classified these indicators into two
categories: direct and indirect. The indirect indicators of
the accuracy of NIFTY test came from the sequencing
procedure: Q20% refers to the fraction of bases within
the sequenced reads with an Illumina quality score
greater than 20, and the PCR duplication rate, refers to
the fraction of the reads sharing the same start position
and end positions on the reference genome. The direct
indicators came from the data analysis procedure and
included the number of unique reads (Figure 2), the
genome-wide average GC content, and the consistency
between the test samples and the reference controls.
Aneuploidy detection with NIFTY test
The NIFTY test performed with 100% sensitivity and spe-
cificity for the detection of trisomy 13 (two out of two)
(Figure 3a) and trisomy 21 (16 out of 16) (Figure 3c). For
trisomy 18, the NIFTY test detected 12 of 12 cases and
identified 890 of 891 healthy controls (Figure 3b), indica-
ting 100% sensitivity and 99.7% specificity, corresponding
to zero false negative results and a false positive rate of
0.3%. The false positive occurred in a sample from ges-
tational week 21. Our GC-correlation t-test approach
correctly detected sex chromosomal abnormalities. For














Figure 2 The required number of of unique reads for high sensitivity
the required number of unique reads (y-axis) increased with decreasing cff
million unique reads are needed to obtain high sensitivity.four XO cases but failed to detect the mosic 45, X case
which was in gestational week of 25 and had a normal
karyotype in 46% of the cells sampled. Thus, the sen-
sitivity and specificity of our approach for the detection of
Turner’s syndrome were 75% and 99.9%, respectively; in
other words, the false negative rate was 25% and false po-
sitive rate was 0.1% for 45, X detection using the NIFTY
test. The test performed with 100% sensitivity and specifi-
city for the detection of XXY (two out of two) or XYY
(one out of one) (Figure 3e and f).
The NIFTY test correctly identified the sex of approxi-
mately 99.9% of the 896 fetuses, 443 male and 452 fe-
male, which did not have sex chromosomal aneuploidies.
The NIFTY test was inconclusive for one fetus that was
determined to be 46, XX by karyotyping.Comparison between different aneuploidy detection
approaches
To evaluate the performance of the NIFTY test in the
detection of fetal aneuploidy, we compared it with the
performance of three other previously reported approa-
ches to analyse our 903 cases, with full karyotyping of
the same 300 euploid cases [23,27,29]. Chiu et al. used
the standard z-score approach without any GC-bias remo-
val to detect Down syndrome [23]. Chen et al. developed
a z-score approach with a different GC-bias removal stra-
tegy [27], which we named the “GC-correct z-score ap-
proach.” Lau et al. previously demonstrated a internal
chromosome control based z-score approach [29].A concentration
across different cff-DNA concentrations. For aneuploidy detection,
-DNA concentration (x-axis). For a 3.5% cff-DNA concentration, 1.7
Figure 3 Fetal aneuploidy detection using NIFTY test. a-c, The k-mer coverage (y-axis) of 903 samples was plotted with corresponding GC
content (x-axis) for chromosome 13,18 and 21. The solid black line is the fit between the k-mer coverage and GC content among the 300
controls. The dot-dash lines from inside to outside are the contour lines of t=1, t=2 and t=3 respectively. d, XO detection. The t-score of
chromosome X for 452 cases with female fetuses and 4 XO cases is dotted. The t-score less than −2.5 indicates XO aneuploidy. e, XXY detection.
The x-axis is the t-score of chromosome X for samples carrying male fetuses. The y-axis is the fetal fraction estimated by chromosome X. Red
square points indicated XXY cases that have a t-score larger than 2.5 and the cff-DNA concentration estimated by chromosome X nearly equal to
zero. f, XYY detection. The x-axis is t-score for chromosome X among samples carrying male fetuses. The y-axis is the R-value, i.e. the ratio of the
fetal DNA fraction estimated by chromosome Y to that estimated by chromosome X. Red triangle points indicate XYY cases with t-score greater
than 2.5 and R-value greater than 2. The case types are color coded (black: testing samples; green: reference samples; red: aneuploidy samples).
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the performances of these four approaches (Figure 4).
Additionally, we found that the CV for the standard z-
score approach was larger than that for other approa-
ches among clinically relevant chromosomes (13, 18 and
21). Thus, the standard z-score approach has a low sen-
sitivity for the detection of trisomies 13 and 18 (Table 1).
The performance of the GC-correct z-score approaches
and our NIFTY test were close, both demonstrated over
99% sensitivity and specificity for the detection of tri-
somy 13, 18 and 21 (Table 1). It was difficult to precisely
detect sex chromosomal aneuploidy using the GC-correct
z-score approach due to fetal gender confusion. The in-
ternal chromosome control approach displayed larger CV
values for chromosomies 13, 18, and 21 and had a higher
risk of false negatives related to XXY and XYY detection.
In contrast, the NIFTY test had increased accuracy in the
detection of sex chromosomal aneuploidies, such as XO,
XXY and XYY (Table 1).Discussion
The cost of high throughput sequencing decreased dramat-
ically over the past few years, thus increasing its utility for
clinical practices [30,31]. In this study, we demonstrated
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Figure 4 The Performance of three methods: coefficient of variation (
(x-axis) for the 903 samples with karyotyping. The different methods are th
Dark Blue: Standard z-score approach; Light Blue: Internal chromosome con
(13, 18, 21), our approach obtained the lowest CVs, indicating a higher sennoninvasively detecting fetal aneuploidies. the NIFTY test
proved to be a reliable and timely method for detecting
both autosomal and sex chromosomal aneuploidies, espe-
cially trisomy 21, trisomy 18, trisomy 13, XO, XXY and
XYY.
GC-bias is a common issue for applications using the
current massively parallel sequencing platforms, and it
can be introduced either by sample preparation or the
sequencing procedure [32,33]. In this study, we observed
that sequencers appear to have a preferred GC ranges,
and the differences in GC composition among different
chromosomes can act as an intrinsic factor influencing the
degree of data fluctuation. We employed GC-correlation
to significantly reduce the effect of GC-bias. Using the
same reagents for library construction and sequencing,
and improving the image analysis software may be useful
in further minimizing the GC-bias.
The small fetal DNA fraction in the maternal blood
was the main limitation on sequencing dependent non-
invasive prenatal diagnosis. The required number of uni-
que reads increases exponentially when the concentration
of cff-DNA falls to less than 3.5%, which is consistent with
the results of a previous study [27]. An advantage of our
approach is that the quality-control procedure uses the es-
timation of cff-DNA concentration as a key index. Thus,
the quality-control procedure, improves the accuracy ofmosome name
core approach
re approach
some control based z−score approach
0 11 12 13 14 15 16 17 18 19 20 21 22
CV). We calculated the CVs (y-axis) among the different chromosomes
e color-coded (Orange: NIFTY test; Green: GC correct z-score approach;
trol based z-score approach). In the clinically interesting chromosomes
sitivity.
Table 1 The performance of four approaches for detection of fetal aneuploidy
Test Standard z-score approach GC correct z-score approach Internal chromosome control
based z-score approach
NIFTY test
(Number of cases) Sensitivity Specificity Sensitivity Specificity Sensitivity Specificity Sensitivity Specificity
Autosome T13 (2) 50%(1/2) 99.9%(900/901) 100%(2/2) 100%(901/901) 100%(2/2) 99.7%(898/901) 100%(2/2) 100%(901/901)
T18 (12) 91.7%(11/12) 100%(891/891) 100%(12/12) 99.9%(890/891) 100%(12/12) 100%(891/891) 100%(12/12) 99.9%(890/891)
T21 (16) 93.7%(15/16) 100%(887/887) 100%(16/16) 100%(887/887) 100%(16/16) 100%(887/887) 100%(16/16) 100%(887/887)
Sex chromosome* 45, X (3 45, X, 1 45,X/46,XX) Not available Not available Not available Not available 75%(3/4) 99.8%(897/899) 75%(3/4) 99.9%(898/899)
XYY (1) Not available Not available Not available Not available 0%(0/1) 100%(902/902) 100%(1/1) 100%(902/902
XXY (2) Not available Not available Not available Not available 0% (0/2) 100%(901/901) 100%(2/2) 100%(901/901)
Binary hypothesis Not available Not available Available Available
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methodology over previous methods is the change from
sole reliance on a binary hypothesis to a more comprehen-
sive statistical model. Our statistical model strengthens
the theoretical sensitivity of the test; the NIFTY test per-
formed with 100% sensitivity and 99.9% specificity for
detecting autosomal aneuploidies and 85.7% sensitivity
and 99.9% specificity for detecting sex chromosomal
aneuploidies.
Using the NIFTY test we treated each chromosome as
a whole, which allowed us to focus on detecting the
aneuploidies. In principle, we could detect other chro-
mosomal abnormalities resulting in serious clinical conse-
quences, such as microdeletions and microduplications,
by slicing the chromosomes into smaller fragments and
increasing the number of sequencing tags. It is also
possible to detect mutations, such as those under-
lying Mendelian diseases, in genes or regions of interest
through target region capture and high depth sequen-
cing [34].
Although we achieved high detection accuracy in a co-
hort of 903, the sample size in this study was a limiting
factor because the incidence of aneuploidies in the gen-
eral population is low. To precisely estimate sensitivity
and specificity of our procedure, large-scale, multi-
center clinical trials will be required in the future.
Additionally, the conventional approaches for cff-DNA
concentration estimation are mostly locus-specific and
only applicable to limited population [20,35]. Our ap-
proach was also less accurate in assessing the cff- DNA
concentration for female fetuses. Further studies should
focus on developing an unbiased method to precisely
estimate the fraction of cff-DNA in the maternal plasma.
Conclusions
In this study we demonstrate a robust and accurate
methodology to detect fetal aneuploidies using MPS.
This is the first study to systematically identify sex chro-
mosomal aneuploidies with maternal plasma DNA se-
quencing. We hope the use of this method in clinical




From June 2009 to August 2010, we recruited a total
of 903 participants prospectively from the Shenzhen
People’s Hospital, the Zhuhai Municipal Maternal and
Child Healthcare Hospital and the Shenzhen Maternal
and Child Care Center. We recruited another 19 euploid
adult males for the estimation of fetal DNA fraction. In-
stitutional Review Board approval was obtained at each
site, and all participants gave informed written consent.
We obtained the full karyotyping results for all samplesfrom regular clinical tests. We randomly selected 300
euploid samples among the karyotyping results to use as
the reference controls.Maternal plasma DNA sequencing
We collected five ml peripheral venous blood from 903
pregnant women in EDTA tubes. The tubes were centri-
fuged at 1,600 × g for 10 min within four hours of col-
lection. Plasma was transferred to microcentrifuge tubes
and centrifuged at 16,000 × g for 10 min to remove re-
sidual cells. Cell-free plasma was stored at −80°C until
DNA extraction. Each plasma sample was frozen and
thawed only once.
For massively parallel genomic sequencing, DNA frag-
ments from 600 ul of maternal plasma were used for
library construction according to a modified protocol
from Illumina. End-repairing of maternal plasma DNA
fragments was performed using T4 DNA polymerase,
Klenow polymerase, and T4 polynucleotide kinase.
Afterwards, A-base tailing adapters were ligated to the
DNA fragments. Standard multiplex primers were intro-
duced by 17-cycle PCR. The libraries were analysed for
size distribution by Agilent Bioanalyzer and quantified
using real-time PCR. Thirty-six-cycle single-end multi-
plex sequencing and 50-cycle single-end multiplex se-
quencing were used for the Illumina GAIIx and
Illumina HiSeq 2000 platform, respectively.High effective alignment with universal unique reads set
Computationally, we incised the human reference ge-
nome (HG 18, NCBI build 36) into k-mers (k refers to
the length of the sequencing reads) and then aligned the
k-mers back to the reference genome. All of the k-mers
that could be uniquely mapped to a single position on
the reference genome, the unique mapping reads, were
named as the universal unique reads set. We selected the
sequencing reads that could be mapped with 0-mismatch
to the universal unique reads set (i.e. the tag) for our
analysis.K-mer coverage and GC-correlation
We computed the k-mer coverage for each chromosome
and every sample, as Ci;j ¼ ni;jNi where is the ID of control
samples; j is the chromosome ID; ni,j is the number of
unique reads mapped onto chromosome j from sample i
and Ni,j was the total number of unique reads for
chromosome j. Because of the differences among the
samples, we normalized the data and computed the rela-




j¼1Ci;j was the average k-mer coverage of the
22 autosomes in the i-th sample.
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formed a Losses regression to fit the relative k-mer
coverage to the corresponding GC content. We denoted
the fitted relative k-mer coverage as cr0i,j = fj(GCi,j). The
fitted value, which we used as the theoretical value, was
vital to our statistical model for cff-DNA concentration
estimation and aneuploidy detection.
Because we using a male/female data set, we had dif-
ferent fitted values for the analysis of sex chromosomes.
We calculated the fitted relative k-mer values for the sex
chromosome analysis as follows:
cr0i,j,m = fj,m(GCi,j) · (j = X,Y), for the fitted relative k-mer
coverage from a regression of an adult male data set;
and
cr0i,j,f = fj,f(GCi,j) · (j = X,Y), for the fitted relative k-mer
coverage from a regression of a fetal-female data set.
Cff-DNA concentration estimation
Using the gender difference to compute the relative k-
mer coverage of the sex chromosome, we estimated the
cff-DNA concentrations, which denote as ε. Subscripts
corresponding to chromosome IDs indicate concentra-









cr0 i;Y ;mcr0 i;Y ;f , is the estimation using data forchromosome X.Autosomal aneuploidy detection with binary hypothesis
We developed a binary hypothesis strategy to achieve a
higher sensitivity and specificity. We performed two Stu-
dent’s t-test based on null/alternative hypotheses, and
we subsequently calculated the relative logarithmic like-
lihood odds ratio. The null and alterative hypothesizes
are shown below.
For the first test:
H0 (null hypothesis): the fetal chromosome was euploid.
H1 (alterative hypothesis): the fetal chromosome was
trisomic.





For the second test:
H0 (null hypothesis): the test fetal chromosome
was trisomic.
H1 (alterative hypothesis): the test fetal chromosome
was euploid.




.The logarithmic likelihood odds ratio between our bi-






where DOF = the degree of freedom., We used, │ti;j;first│
> 3 and │ti;j;second│< 3 as warning criteria. From the loga-
rithmic likelihood odds ratio, we could make a confident
judgment of autosomal aneuploidy if Li;j > 1.
Fetal gender classification and sex chromosomal
aneuploidy detection
We developed a double standard strategy with an experi-
mental threshold and logistic regression to detect the
fetal gender. The k-mer coverage on chromosome Y was
an ideal choice for distinguishing genders. Based on the
300 reference controls, we considered cri,Y < 0.04 the
threshold for identifying a female fetus, while we regar-
ded samples with cri,Y > 0.051 as having a male fetus.
We considered samples with 0.04 < cri,Y < 0.051 to be
gender-uncertain.
Additionally, we developed a logistic regression stra-
tegy to improve the specificity of the gender determi-
nation. We computed the probability (Pi) of that a fetus
was male by the following formula:
logit pið Þ ¼ ln pi1pi
 
¼ β0 þ β1cri;X þ β2cri;Y , where the
parameters (β0, β1, β2) were determined by regression
using the 300 reference controls mentioned above.
We regarded samples with pi > 0.8 as having male
fetuses, samples with pi < 0.3 as having female fetuses,
and the remaining samples as being gender-uncertain.
After gender classification, we performed XXX and
XO detection on samples with a female fetus and XXY
and XYY detection on samples with a male fetus.
For samples with a female fetus, we performed a t-test





where sdX,f is the standard deviation of
cri,X,f − cr
0
i,X,f calculated from the reference controls with
female fetuses; we expected sdX,f to equal zero. We con-
sidered samples with ti,X or ti,X < -2.5 to be XXX or XO.
For a male fetus, we first supposed that chromosome
Y is monosomic and extrapolated the fitted k-mer cover-
age for chromosome X, with the fetal DNA fraction esti-
mated only by the k-mer coverage of chromosome Y.






, where εi,Y is the estimated cff-
DNA concentration using chromosome Y data, and is the
standard deviation of cri,X,f − cr
0
i,X,f calculated from the
reference controls carrying female fetuses with an expec-
tation of zero. Both of these quantities are defined above.
We regarded samples with ti >2.5 as being XXY or
XYY. Additionally, the cff-DNA concentration estimated
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marker for sex chromosomal aneuploidy detection espe-
cially XXY and XYY. For an XXY sample, not only was
the ti >2.5 but also the cff-DNA concentration estimated
by chromosome X was nearly zero, with a confidence
interval from −0.03 to 0.03; For an XYY samples, not
only the ti >2.5, but the R-value (Ratio of the cff-DNA
concentration estimated by chromosome Y to that esti-
mated by chromosome X) was nearly two, reflecting the
fact that there were two copies of chromosome Y and
only a single copy of chromosome X.
Additional files
Additional file 1: Figure S1. The correlation between sequence GC
content and relative k-mer coverage. We plotted the relative k-mer
coverage of each chromosome (y-axis) among our 300 controls against
the corresponding sequence GC content (x-axis). Red plot are for female
fetuses and black plot are for male fetuses.
Additional file 2: Figure S2. The tendency between normalized k-mer
coverage and corresponding GC content. The GC content of each
chromosome is listed in orders. The blue bars refer to the chromosomes
that have a negative correlation between the k-mer coverage and the GC
content, green bar refer chromosomes that have a positive correlation
between the k-mer coverage and the GC content, and yellow bar refer to
the chromosomes with no correlation.
Additional file 3: Figure S3. The reconstructed relationship between
chromosomes by GC content. We reconstructed the GC-content
relationship between the different chromosomes by clustering the 35-
mer counts for 36 GC levels (y-axis) on the different chromosomes (x-
axis). The normalized 35-mer counts, as a percentage of each
chromosome, are color-coded in the heat map.
Additional file 4: Figure S4. The relationship between estimated cff-
DNA concentration and gestational week. The black dots represent the
cff-DNA concentrations (y-axis) plotted against the corresponding
gestational week (x-axis) for the 443 samples with male fetuses.
Additional file 5: Figure S5. The standard deviation and sample
numbers. The standard deviations of the difference between the
observed and fitted k-mer coverage (y-axis) for different numbers of
samples (x-axis). Different chromosomes are colour-coded. The standard
deviation becomes stable when the number of samples is larger than
100.
Additional file 6: Figure S6. The relationship between tags number
and the standard deviation of relative k-mer coverage among 150
samples. The standard deviations of the relative k-mer coverage (y-axis)
declines with the increasing number of tags (x-axis) from 0.5 to 3.5
million for each chromosome.
Additional file 7: Figure S7. The aneuploidy detection power
estimation. The colored contour lines show the aneuploidy detection
power at different gestational weeks (x-axis) and with different numbers
of unique reads (y-axis).Fetal genders are shown separately. The power is
much higher when the fetus is male.
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